Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Sutro Biopharma, Inc. has granted stock options and restricted stock units to new non-executive employees as an inducement for their acceptance of employment [1][2] Group 1: Stock Options and RSUs - The Compensation Committee granted stock options to purchase 24,500 shares and 2,000 RSUs [1] - The stock options will vest one-fourth on the one-year anniversary of the hire date and monthly thereafter until fully vested on the fourth anniversary [2] - The RSUs will vest one-fourth on the one-year anniversary of the hire date and annually thereafter until fully vested on the fourth anniversary [2] Group 2: Company Overview - Sutro Biopharma is focused on advancing a next-generation antibody-drug conjugate (ADC) platform aimed at improving cancer treatment [3] - The company’s platform is designed to produce single- and dual-payload ADCs that enhance drug exposure, reduce side effects, and expand treatable tumor types [3] - Sutro's pipeline targets large oncology markets with limited treatment options, addressing significant needs for improved therapies [3]